Dr. Kane on High-Penetrance Genetic Syndromes in Prostate Cancer

Christopher J. Kane, MD
Published: Tuesday, Mar 07, 2017



Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses high-penetrance genetic syndromes in patients with prostate cancer.

Many urologists don’t think of prostate cancer as one of the high-penetrance genetic syndromes, especially when compared to kidney cancer, Kane explains.

About 5% to 8% of patients with kidney cancer have a genetic autosomal dominant high-penetrance syndrome. Understanding the recommendation for testing for these syndromes will influence how to tackle the emerging evidence of the genomic and genetic prostate cancer risk, explains Kane.
 
SELECTED
LANGUAGE


Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses high-penetrance genetic syndromes in patients with prostate cancer.

Many urologists don’t think of prostate cancer as one of the high-penetrance genetic syndromes, especially when compared to kidney cancer, Kane explains.

About 5% to 8% of patients with kidney cancer have a genetic autosomal dominant high-penetrance syndrome. Understanding the recommendation for testing for these syndromes will influence how to tackle the emerging evidence of the genomic and genetic prostate cancer risk, explains Kane.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x